TABLE 2.
Name | Mechanism/effect | Target disease | References |
---|---|---|---|
N‐acetylcysteine | ↓Toxic arachidonic acid products of nuclear ALOX5 | HS | 296 |
ADA‐409‐052 |
↓TBHP‐induced lipid peroxidation ↓Activation of BV2 microglia Maintain mitochondrial morphology |
IS | 299 |
---|---|---|---|
Thiazolidinediones | ↓ACSL4 activity selectively | IS | 300 |
Baicalin | ↑The mRNA expression of GPX4 and SLC7A11 in the peri‐hematoma brain tissues | HS | 303 |
---|---|---|---|
Dauricine | ↑GPX4 and glutathione reductase coexpression | HS | 304 |
Melatonin | ↓5‐LOX level by circPtpn14/miR‐351‐5p signaling | TBI | 305 |
---|---|---|---|
DHI | ↑SATB1/SLC7A11/HO‐1 pathway | IS | 306 |
β‐Caryophyllene | ↑Nrf2/HO‐1 signaling pathway | IS | 307 |
---|---|---|---|
Eriodictyol |
|
AD | 308 |
α‐Lipoic acid |
↓p‐tau Iron redistribution mediated by TfR and Fpn1 |
PD | 309 |
---|---|---|---|
TS, TP | Inhibit 15‐LOX by competing for the substrate binding site of PUFA | _ | 310 |
Note: ↑, activate/upregulate;↓, inhibit/suppress.
Abbreviations: HS, hemorrhagic stroke; SSAT1, spermidine/spermine N1‐acetyltransferase 1; ALOX5, arachidonate 5‐lipoxygenase; IS, ischemic stroke; TfR1, transferrin receptor 1; DMT1, divalent metal transporter 1; SLC7A11, solute carrier family 7 member 11; GPX4, glutathione peroxidase 4; GSH, glutathione; TBHP, tert‐Butyl hydroperoxide; ACSL4, Acyl‐CoA synthetase long‐chain family member 4; LPCAT3, lysophosphatidylcholine acyltransferase 3; 5‐LOX, 5‐lipoxygenase; TBI, traumatic brain injury; DHI, danhong injection; SATB1, special AT‐rich sequence‐binding protein 1; SLC7A11, solute carrier family 7 member 11; HO‐1, heme oxygenase‐1; Nrf2, nuclear factor erythroid 2‐related factor 2; Aβ, β‐amyloid; VDR, vitamin D receptor; p‐tau, phosphorylated tau; TfR, transferrin receptor; Fpn1, ferroportin 1; TS, α‐Tocopherol succinate; TP, α‐Tocopherol phosphate; 15‐LOX, 15‐lipoxygenase; PUFA, polyunsaturated fatty acids.